Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where XBP declined for three days, in 200 of 226 cases, the price declined further within the following month. The odds of a continued downward trend are 88%.
The Momentum Indicator moved below the 0 level on October 14, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on XBP as a result. In 58 of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 67%.
The Moving Average Convergence Divergence Histogram (MACD) for XBP turned negative on October 01, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 27 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 56%.
XBP moved below its 50-day moving average on October 19, 2026 date and that indicates a change from an upward trend to a downward trend.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +5.08% 3-day Advance, the price is estimated to grow further. Considering data from situations where XBP advanced for three days, in 111 of 161 cases, the price rose further within the following month. The odds of a continued upward trend are 69%.
XBP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 91 of 248 cases where XBP Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 37%.
The Tickeron Valuation Rating of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.870) is normal, around the industry mean (15.930). P/E Ratio (-0.549) is within average values for comparable stocks, (56.422). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.648). Dividend Yield (0.000) settles around the average of (0.209) among similar stocks. P/S Ratio (0.051) is also within normal values, averaging (103.889).
The Tickeron PE Growth Rating for this company is 51 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating fairly steady price growth. XBP’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XBP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
The RSI Indicator for ZCMD moved out of oversold territory on October 14, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 34 similar instances when the indicator left oversold territory. In 29 of the 34 cases the stock moved higher. This puts the odds of a move higher at 85%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +7.63% 3-day Advance, the price is estimated to grow further. Considering data from situations where ZCMD advanced for three days, in 131 of 174 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
ZCMD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on October 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ZCMD as a result. In 106 of 115 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
ZCMD moved below its 50-day moving average on October 06, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ZCMD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for ZCMD entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 62 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.638) is normal, around the industry mean (4.100). P/E Ratio (-0.023) is within average values for comparable stocks, (13.263). Projected Growth (PEG Ratio) (0.800) is also within normal values, averaging (2.133). Dividend Yield (0.000) settles around the average of (0.012) among similar stocks. P/S Ratio (0.002) is also within normal values, averaging (6.065).
The Tickeron Price Growth Rating for this company is 94 (best 1 - 100 worst), indicating slightly worse than average price growth. ZCMD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ZCMD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 97, placing this stock worse than average.
ZCMD | ||
|---|---|---|
OUTLOOK RATING 1..100 | 45 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 62 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 97 | |
PRICE GROWTH RATING 1..100 | 94 | |
P/E GROWTH RATING 1..100 | 8 | |
SEASONALITY SCORE 1..100 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| XBP | ZCMD | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 85% |
| Stochastic ODDS (%) | 2 days ago 64% | 2 days ago 84% |
| Momentum ODDS (%) | 2 days ago 67% | 2 days ago 90% |
| MACD ODDS (%) | 2 days ago 56% | N/A |
| TrendWeek ODDS (%) | 2 days ago 76% | 2 days ago 90% |
| TrendMonth ODDS (%) | 2 days ago 82% | 2 days ago 90% |
| Advances ODDS (%) | 11 days ago 69% | 3 days ago 75% |
| Declines ODDS (%) | 3 days ago 88% | 10 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 79% | 2 days ago 81% |
| Aroon ODDS (%) | 2 days ago 37% | 2 days ago 90% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
XBP’s FA Score shows that 1 FA rating(s) are green while ZCMD’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
XBP’s TA Score shows that 4 TA indicator(s) are bullish while ZCMD’s TA Score has 4 bullish TA indicator(s).
XBP (@Computer Communications) experienced а -5.15% price change this week, while ZCMD (@Services to the Health Industry) price change was -2.90% for the same time period.
The average weekly price growth across all stocks in the @Computer Communications industry was -1.36%. For the same industry, the average monthly price growth was -9.84%, and the average quarterly price growth was +4.51%.
The average weekly price growth across all stocks in the @Services to the Health Industry industry was -1.51%. For the same industry, the average monthly price growth was -3.63%, and the average quarterly price growth was +16.27%.
XBP is expected to report earnings on Nov 13, 2026.
Computer communications industry develops technology that allows computing devices to exchange data with each other using connections/data links between nodes. Common types of computer network include Cloud (IAN), Internet, Wide (WAN, Local (LAN)/Wireless(WLAN) etc. The industry is an ever-more important part of technology, and is set to become even bigger as the Internet of Things (IoT) rapidly forays into the various aspects of our lives. Cisco Systems, Inc., Palo Alto Networks, Inc. and Arista Networks, Inc., Fortinet, Inc. are some of the major computer communications companies.
@Services to the Health Industry (-1.51% weekly)This industry comprises companies that provide services, such as equipment sterilization, research, physician management systems and consulting, that support the healthcare/medical industry. Examples of such companies include Laboratory Corporation of America Holdings, which operates one of the largest clinical laboratory networks in the world; Quest Diagnostics Inc., which is a clinical laboratory; and Syneos Health, which is a major clinical research organization.
A.I.dvisor tells us that XBP and SMSI have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that XBP and SMSI's prices will move in lockstep.
| Ticker / NAME | Correlation To XBP | 1D Price Change % | ||
|---|---|---|---|---|
| XBP | 100% | +1.60% | ||
| SMSI - XBP | 32% Poorly correlated | +0.20% | ||
| NUTX - XBP | 27% Poorly correlated | -0.69% | ||
| PHUN - XBP | 27% Poorly correlated | -0.99% | ||
| DRK - XBP | 23% Poorly correlated | N/A | ||
| IIIV - XBP | 23% Poorly correlated | -0.76% | ||
More | ||||
A.I.dvisor tells us that ZCMD and ZETA have been poorly correlated (+22% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ZCMD and ZETA's prices will move in lockstep.
| Ticker / NAME | Correlation To ZCMD | 1D Price Change % | ||
|---|---|---|---|---|
| ZCMD | 100% | -4.96% | ||
| ZETA - ZCMD | 22% Poorly correlated | +1.67% | ||
| SOHU - ZCMD | 21% Poorly correlated | -0.44% | ||
| PEGA - ZCMD | 21% Poorly correlated | -2.90% | ||
| XBP - ZCMD | 21% Poorly correlated | +1.60% | ||
| CHKP - ZCMD | 20% Poorly correlated | +1.83% | ||
More | ||||